← Back

Wire · opportunities

Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided ...

Published

19 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

Abbott has launched the VOYAGER clinical trial to evaluate the Encantor™ software-guided balloon-expandable transcatheter aortic valve implantation (TAVI) system for treating aortic stenosis.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 19 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You can now explore software-guided TAVI platforms as a new frontier in heart valve therapy, opening routes for innovation in minimally invasive cardiology devices. This signalling trial highlights where clinical differentiation can unlock greater adoption and regulatory support.

◆ Coverage

3 sources · first reported 19 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Medtechclinical-trialmedical-devicesoftware-guidedcardiologytavi